Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 4

Research Article

Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 4

Response to treatment in AIH features after 3, 6, and 12 months of therapy.

VariablesOverall (n=28, %)UDCA-only group (n=14), %UDCA+IS group (n=14), %P value

3-month remission4(14.2%)0(0%)4(28.6%)0.098
6-month remission6(21.4%)1(7.1%)5(35.7%)0.165
12-month remission7(33.3%)#1(9.1%)##6(60.0%)0.024

Twenty-one patients were treated for more than 12 months in total.
#Eleven patients were treated for more than 12 months in the UDCA-only group.
##Ten patients were treated for more than 12 months in the UDCA+IS group.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.